TUESDAY, May 21 (HealthDay News) -- Less is more when it comes
to steroid therapy for patients having severe bouts of chronic
obstructive pulmonary disease (COPD), according to Swiss
Five days of glucocorticoid treatment with prednisone to treat
COPD flare-ups was as good as the standard 14 days, but with fewer
chances for adverse side effects, they said.
"We wanted to show that a shorter period of treatment was not less effective than 14 days," said lead researcher Dr. Jorg Leuppi, with the department of medicine at the University Hospital of Basel.
The shorter course of treatment had the same outcome as the
longer course of treatment, the study found. "There is exactly the
same time to recovery and exactly the same number of
re-exacerbations," Leuppi said.
In addition, the shorter course of treatment meant fewer side
effects from the drug, such as increased blood pressure and
elevated blood sugar, he said.
The report was published May 21 in the online edition of the
Journal of the American Medical Associationto coincide with
its Tuesday presentation at the American Thoracic Society meeting
COPD is a progressive disease involving bronchitis and emphysema
-- often tied to smoking -- that makes it hard for patients to
breathe. Patients periodically have flare-ups or exacerbations,
when symptoms are at their worst.
Prednisone is a glucocorticoid pill that acts as an
anti-inflammatory. Since a generic version is available, it is a
relatively low-cost therapy.
"COPD exacerbations, which are the leading cause of medical hospitalization in the U.S. and elsewhere, can be treated with a five-day course of prednisone, which is a corticosteroid, not 10 to 14 days as recommended by most national and international guidelines," said Dr. Don Sin, a professor of medicine at the University of British Columbia, in Vancouver, and co-author of an accompanying journal editorial.
Corticosteroids are highly toxic drugs, he said. "Thus, by using
a five-day versus a 10- to 14-day [course], we will prevent many
steroid-related complications -- such as diabetes, osteoporosis and
adrenal insufficiency -- without sacrificing any of the benefits of
steroids for management of COPD exacerbations," he said. "There is
no rationale for giving more steroids than this."
For the study, Leuppi's team randomly assigned more than 300
patients suffering from an acute COPD exacerbation to daily doses
of prednisone for either five or 14 days.
The goal of the study was to see whether either treatment
resulted in fewer new exacerbations of COPD over six months.
The researchers found that prednisone treatment resulted in
about the same number of patients having new bouts of COPD. Among
those who got five days of therapy, 56 had a new bout within six
months; 57 patients given 14 days of therapy had a new
The average time to a new exacerbation of COPD was 43.5 days in
the short-term treatment group and 29 days in the standard
treatment group, the researchers said.
Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital
in New York City, said that "while treatment with corticosteroids
is often necessary in exacerbations of COPD, it has not been clear
how long the treatment should be given."
"The authors found that a shorter duration of treatment with steroids was possible," he said. "The accompanying side effects were less, and total dose of steroids was less long term."
To learn more about COPD, visit the
American Lung Association.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.